| Study Name | Description | Trial Category | Trial SubCategory |
|---|---|---|---|
| NRG BR003 | A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer | Cancer | Breast |
| NRG-GI002 | A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer | Cancer | Gastro-Intestinal |
| NRG-GU002 | Phase II-III Trial of Adjuvant Radiotherapy Following Radical Prostatectomy With or Without Adjuvant Docetaxel | Cancer | Prostate |
| NRG-GY005 | A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS) | Cancer | Gynecology - Ovarian, Fallopian Tube or Primary Peritoneal Cancer |
| OPUS | A registry of patients taking Opsumit for pulmonary hypertension | Heart & Vascular | Hypertension |
| S0820 - Prevention of High-Risk Colorectal Polyps and New Colorectal Cancers | PACES S0820 is a study to determine the efficacy of certain drugs in the prevention of high-risk colorectal polyps and new colorectal cancers in patients with previously treated colorectal cancer. | Cancer | Gastro-Intestinal |
| S1418/BR006 | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy | Cancer | Breast |
| S1507 | A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies | Cancer | Lung |
| S1609 - DART | DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in rare tumors. Single arm nivolumab and ipilimumab treating patients with rare tumors | Cancer | Rare Tumor |
| TAPUR Study for Advanced Cancers | The Targeted Agent and Profiling Utilization Registry (TAPUR) Study is a non-randomized clinical trial that aims to describe the performance (both safety and efficacy) of commercially available, targeted anticancer drugs prescribed for treatment of patients with advanced cancer that has a potentially actionable genomic variant. For more information please visit http://www.tapur.org/patients | Cancer | Genomic testing based trial |
What you need to know about COVID-19 Vaccine, Testing, and Visitor Restrictions